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Abstract
Background: The control of malaria, caused by Plasmodium falciparum, is hampered by the relentless evolution of
drug resistance. Because artemisinin derivatives are now used in the most effective anti-malarial therapy, resistance to
artemisinin would be catastrophic. Indeed, studies suggest that artemisinin resistance has already appeared in natural
infections. Understanding the mechanisms of resistance would help to prolong the effective lifetime of these drugs.
Genetic markers of resistance are therefore required urgently. Previously, a mutation in a de-ubiquitinating enzyme was
shown to confer artemisinin resistance in the rodent malaria parasite Plasmodium chabaudi.
Methods: Here, for a mutant P. chabaudi malaria parasite and its immediate progenitor, the in vivo artemisinin
resistance phenotypes and the mutations arising using Illumina whole-genome re-sequencing were compared.
Results: An increased artemisinin resistance phenotype is accompanied by one non-synonymous substitution. The
mutated gene encodes the μ-chain of the AP2 adaptor complex, a component of the endocytic machinery. Homology
models indicate that the mutated residue interacts with a cargo recognition sequence. In natural infections of the
human malaria parasite P. falciparum, 12 polymorphisms (nine SNPs and three indels) were identified in the
orthologous gene.
Conclusion: An increased artemisinin-resistant phenotype occurs along with a mutation in a functional element of the
AP2 adaptor protein complex. This suggests that endocytosis and trafficking of membrane proteins may be involved,
generating new insights into possible mechanisms of resistance. The genotypes of this adaptor protein can be
evaluated for its role in artemisinin responses in human infections of P. falciparum.
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Background
Without an effective vaccine, prevention and treatment of
human malaria has traditionally relied on chemoprophylaxis
and/or chemotherapy [1]. However, Plasmodium falciparum
has developed resistance to nearly every anti-malarial drug
introduced to date, compromising its control. Resistance
arises via the selection of parasites bearing specific
mutations, and is decisive in determining the effective life-
time of anti-malarial agents.
Artemisinin combination therapy (ACT) is now a widely
used anti-malarial treatment. The artemisinin component
is a highly effective and rapidly acting drug [2]. The under-
standing of its mode of action is incomplete [3,4], but
independent lines of evidence from a number of labora-
tories suggest that its action depends upon its endoperox-
ide group and activation by haem or other iron sources [3].
Downstream, it may localize close to the digestive vacuole
(DV) [5] and effect changes in DV morphology [6] or the
distribution, endocytosis and digestion of haemoglobin [7].
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Alternatively, it has been suggested that artemisinin may
inhibit the Ca2+-ATPase (PfATP6) [8].
Alarmingly, recent data indicate that resistance to
artesunate, one of several artemisinin derivatives (ARTDs),
is emerging in Cambodia and Thailand [9-14]. Molecular
(DNA) markers of resistance are therefore required ur-
gently. These tools will help to monitor the evolution of
resistance, to establish rational treatment policies and to
design drug combinations that delay the evolution of re-
sistance. At present however, in P. falciparum, there are
no universally accepted and validated molecular markers
of artemisinin resistance in the field. Polymorphisms in
PfATPase6 [15,16] or amplification of the multidrug resist-
ance gene, Pfmdr1 [17-19] have been investigated. However,
no correlation was found between variants of these genes
and in vivo responses to ARTDs in the first suggested cases
of resistance along the Thai/Cambodian border [20,21].
Candidate gene approaches may not focus on the critical
genes nor grasp the full complexity of the drug response
mechanisms. Instead, analysis of genetic haplotype vari-
ation and conservation and geographic differentiation using
genome-wide SNP typing of P. falciparum parasites from
Southeast Asia (Thailand, Cambodia and Laos), where
resistance to ARTDs is emerging, has identified candi-
date regions associated with slow parasite clearance rates
after drug treatment [21], particularly in a region on chro-
mosome 13. No specific genes in this region were identified
as candidates for influencing artemisinin response.
Other experimental studies that do not prejudge the
critical genes are especially informative; for example, the
in vitro generation of mutant P. falciparum parasites
resistant to drugs. Parasites resistant to ARTs have been
generated and mdr1 duplications identified [22], but often
the phenotypes and genetic changes have tended to be
unstable in the absence of drugs [23,24]. Genetic linkage
analysis of the experimental P. falciparum Hb3 x Dd2
cross has shown that three loci, including pfmdr1 and
two additional loci (on chromosomes 12 and 13) [24] that
were associated with artemisinin (ART) responses or the
potential to evolve ART resistance, but neither of these
parental parasites offered a distinct ART-R phenotype.
In vivo experimental studies using the rodent malaria
Plasmodium chabaudi can circumvent some limitations
faced by in vitro experimentation. A lineage (strain AS)
of genetically stable mutant parasite clones that are re-
sistant to various drugs has been generated by experi-
mental evolution under drug selection (Figure 1). The
genetic mutations conferring resistance to pyrimethamine,
sulphadoxine, chloroquine, mefloquine, lumefantrine and
artemisinin have been mapped using efficient genetic link-
age mapping (population based genome-wide scans of
selection) and Illumina whole-genome sequencing [25-28].
The identification of the critical mutations exploits
four important features relevant to the present study.
Firstly, the resistance phenotype appears at the same
time/position in the lineage as the critical mutation.
Secondly, the mutation will lie at the bottom of a ‘selection
valley’ (genomic region selected by drug). Thirdly, these
studies exploited a previously completed reference genome
sequence isogenic to the progenitor parasite, AS-sens.
Fourthly, the numbers of point mutations (genome-wide)
fixed at each step by selection or during cloning are very
small, typically 1–3 [26].
For artemisinin, a mutation in a de-ubiquitinating
enzyme (V2728F ubp1) was proposed previously as the
critical determinant of an artemisinin-resistance (ART-R)
phenotype [25] in parasite AS-30CQ (Figure 1). This ubp1
mutation has also been shown to contribute to resistance
to mefloquine and lumefantrine [27] and higher doses of
chloroquine [26], as well as ARTs, suggesting that ubp1
may mediate parasite responses to multiple drugs, as does
mdr1 duplication [27].
Here, another parasite, AS-ART (Figure 1), derived from
AS-30CQ after prolonged and progressive ART selection
[29], is investigated. An increased ART-R phenotype is
characterized and a single point mutation in its genome
is defined. The 3D structures of homologues of the mu-
tated protein are investigated for possible functional conse-
quences. Allelic variations of the P. falciparum orthologue
of the mutated gene are defined in a set of P. falciparum
field samples.
Methods
Ethics
All animal work was conducted according to relevant
national and international guidelines: in Portugal, after
approval by the Ethics Committee of the Instituto de
Higiene e Medicina Tropical of Lisbon, Portugal, under
PARECER 2/2006 from 1 August, 2006 and in the UK,
in compliance with the UK Animals (Scientific Procedures)
Act 1986.
Parasite lines, maintenance, parasite preparation and
DNA extraction
All the parasite clones used in this study are members
of the AS lineage (Figure 1). Three parasite clones were
used: i) AS-3CQ, a parasite that is resistant to low levels
of chloroquine [34]; ii) AS-30CQ, that is resistant to high
levels of chloroquine [34]; and, iii) AS-ART, which was
derived from AS-30CQ through multiple sub-inoculations
in mice under increasing doses of artemisinin (ART) [29].
All parasites were routinely inoculated, passaged in CBA
mice (four to six weeks) and cryopreserved as previously
described [30]. Parasites were prepared and DNA extracted
as previously described [35], ensuring that host white
cells were removed by CF11 cellulose (Whatman) and
Plasmodipur filters (Eurodiagnostica). DNA samples from
other clones within the lineage were used to determine
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the earliest appearance of specific mutations within the
lineage. All animal work was conducted according to rele-
vant national and international guidelines: in Portugal,
after approval by the Ethics Committee of the Instituto de
Higiene e Medicina Tropical of Lisbon, Portugal, under
PARECER 2/2006 from August 1st 2006 and in the UK,
in compliance with the UK Animals (Scientific Procedures)
Act 1986.
In vivo ART drug tests
In vivo ART response phenotypes were assessed as fol-
lows. Four to six-week-old inbred CBA mice were divided
into nine groups of three mice each. Mice in groups 1–3
were inoculated with 10exp6 parasitized red blood cells
(pRBC) of AS-3CQ, AS-30CQ or AS-ART, respectively
and given the diluting solvent DMSO orally (untreated
controls). Treatment groups 4–6 were inoculated with
10exp6 pRBC of either AS-3CQ, AS-30CQ or AS-ART
and treated with an oral daily dose of 200 mg ART kg-1
mouse bodyweight, administered for a total of three con-
secutive days, starting day 1 post-inoculum (pi). Treat-
ment groups 7–9 were inoculated with 10exp7 pRBC of
either AS-3CQ, AS-30CQ or AS-ART and treated with
200 mg ART kg-1 mouse bodyweight, administered for a
total of five consecutive days. Individual percentage (%)
parasitaemia was followed from day 4 pi onwards and up
to day 15 in the case of untreated control mice. For treated
mice, % parasitaemia was first assessed one day after the
last day of treatment and up to day 18 pi. Results were
expressed as daily average % parasitaemia ± standard error
from the three mice within each experimental group.
Genome-wide resequencing
Clone AS-sens was previously resequenced with the
IlluminaW platform using 36 bp single reads [25]. Clone
AS-ART was also re-sequenced using 36 bp single-end
reads. Individual sequence strings (reads) from AS-sens
and AS-ART were aligned against the isogenic AS refer-
ence genome assembly (AS-WTSI [36], provided by
the Wellcome Trust Sanger Institute, using two different
software packages: MAQ (Mapping and Assembly with
Quality) [37] and SSAHA2 (Sequence Search and Align-
ment by Hashing Algorithm) [38]. The AS-WTSI se-
quence data consisted of a recently completed assembly
and annotation made available during this investigation.
Detection of SNPs was performed with Samtools [39]
and MAQ, using default parameters, as described in
Hunt et al. [25]. Small (≤3 bp) indels were detected
using Samtools internal algorithm only. The list of sin-
gle nucleotide polymorphisms (SNPs) and small indels
were further filtered by removing mutations proposed for
both AS-sens and AS-ART and that therefore did not arise
within the AS lineage. Heterozygous and “multiple variant”
SNPs, as well as small indels called by less than three reads
and less than 50% of the total reads were also removed.
Larger indels (>3 bp) and CNVs were detected with both
Figure 1 The AS lineage of drug resistant parasites, featuring artemisinin (ART) phenotypes and ubp-1 genotypes. Parasites were
selected by passage in presence of drugs shown [29-33]. Artemisinin resistance (phenotype 1) appears during selection by chloroquine [25,26]
and is mediated by either of two mutations in the ubp-1 gene (PCHAS_020720) [25,27]. AS-ART was generated during selection by artemisinin
[29]. Its increased resistance to artemisinin (phenotype 2) and its genotype is the subject of the present study. *, parasites used in the present
study; wt, wild-type; kg bw, kilograms body weight.
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MAQ and SSAHA2 using “comparative coverage” analysis,
which measures the ratio of the relative coverage (local
coverage divided by overall mean coverage) in AS-ART
relative to AS-sens. A comparative coverage ratio >1.5 over
200 bp for defining CNVs and <0.25 over 10 bp for defin-
ing indels (both adjusted for different genome coverage in
AS-sens and AS-ART) were used, as previously described
[25]. Unlike previous work, “comparative coverage” analysis
was also performed using MAQ. This required running the
“pileup” command on both the AS-ART and AS-sens reads
using the variable “-q 1” (which excludes reads with a map-
ping quality <1). The pileup files thus produced were then
used for “comparative coverage” analysis with custom
made scripts, similarly to the SSAHA2 approach. Confi-
dence levels were assigned to mutations based on the
following criteria: a) Samtools quality scores (for SNPs)
and b) identification by both MAQ and Samtools (for
SNPs and large indels/CNVs). All high confidence putative
point mutations proposed by MAQ and/or Samtools were
verified by di-deoxy sequencing. Only limited verification
was done for potential indels and CNVs. Small indels were
defined as “low confidence” mutations by default, due to
a majority of calls being confirmed as false positives by
di-deoxy sequencing in this and other studies [25,28].
Protein structure-function analysis
The P. chabaudi AP2-μ sequence was used to search the
protein structure database (PDB) for homologues. The
closest match found was the μ chain of AP2 from Rattus
norvegicus, with a bit score of 167 and an E-value of 2e-41.
11 different structure entries of this and related proteins
and complexes were present in the PDB. Structure 2PR9
was selected because of the level of R-factors (R: 0.204,
R-free: 0.240) and its resolution (2.51Å).
The I-TASSER server [40] was used to construct a
homology model of the P. chabaudi homologue, with the
R. norvegicus 2PR9 structure as a template onto which the
P. chabaudi sequence was modelled. The same method
was used to construct a P. falciparum μ model.
Plasmodium falciparum ap2-μ genotyping
In order to investigate the genetic variation in the P.
falciparum ap2-μ gene in natural infections, DNA was
extracted from field samples collected in Africa and
South America, as well as from the reference strain 3D7,
according to the method described by Plowe and co-
workers [41]. The P. falciparum ap2-μ gene was thus
sequenced in a subset of 24 P. falciparum isolates col-
lected within the scope of previous studies, of which
eight were from Rwanda [42], eight from São Tomé [43]
and eight from Brazil [44].
The sequence of the P. falciparum orthologue of the
ap2-μ gene (accession no. PF3D7_1218300) was retrieved
from PlasmoDB and used as template for designing primers
to amplify its open reading frame using an overlapping
PCR fragment strategy (see Additional file 1). PCR assays
were performed with 1 μl of DNA into a 50 μl mixture
containing 0.2 μM of each primer, 1.5 mM MgCl2, 0.2 mM
deoxynucleoside triphosphates and 1.25 units of GoTaqW
Flexi DNA Polymerase (Promega).
PCR products were analysed by ethidium bromide-stained
agarose 2% gel electrophoresis and sequenced directly in
both sense and antisense directions with the appropriate
PCR amplification primers.
Results
The Plasmodium chabaudi AS-ART phenotype
Here, the ART responses of isogenic parasites of the P.
chabaudi AS lineage are investigated further; namely,
AS-3CQ (ART-S clone), AS-30CQ (ART-R clone) and
the AS-ART (ART-R clone) generated during selection
by ART (Figure 1) [29]. In previous work, artemisinin re-
sistance at 100 mg ART kg-1 (body weight) d-1 was dem-
onstrated in both AS-30CQ and AS-ART relative to other
clones, which preceded them in the AS lineage, including
AS-3CQ [25]. Here, the hypothesis that AS-ART would
resist higher doses of ART than AS-30CQ is tested. Para-
sites were treated for three (1 × 10 exp6 inoculum) or five
(1 × 10 exp7 inoculum) days (treatments A and B, respect-
ively) with a daily dose of 200 mg ART kg-1 d-1 and their
response to the drug was assessed by comparing both peak
parasitaemia and the time taken for each parasite to recru-
desce after treatment.
In the absence of treatment, all three parasite clones pro-
duced their peak parasitaemia of between 23% (AS-ART)
and 40% (AS-30CQ), appearing between days 8 and 9 pi
(Figure 2A). Under either ART treatment A and B however,
no parasites were detected in mice infected with AS-3CQ
over the follow-up period (Figure 2B and 2C). After treat-
ment A, AS-30CQ produced detectable parasites between
days 13–14, with parasitaemia reaching their peak (~12%)
on day 17. However, mice infected with AS-ART presented
more rapid recrudescence (days 8–9), with parasitaemia
reaching ~12% on day 15 after treatment (Figure 2B). A
similar trend was observed after treatment B: mice infected
with AS-30CQ first presented a detectable parasitaemia
between days 13–14 and peak parasitaemia (~10% on
day 18), whilst the AS-ART group recrudesced three
days earlier (Figure 2C) achieving a similar peak parasit-
aemia on day 15.
As previously reported [25] it is concluded that AS-3CQ
is sensitive to ART treatment whereas both AS-30CQ and
AS-ART are resistant. Here, however, at high ART doses,
AS-ART shows both earlier recrudescence and reduced
time to reach peak parasitaemia relative to AS-30CQ. It
is concluded that AS-ART has a higher degree of resist-
ance to ART. Here, this enhanced resistance phenotype
is called ART-R phenotype 2. The response of AS-30CQ
Henriques et al. Malaria Journal 2013, 12:118 Page 4 of 15
http://www.malariajournal.com/content/12/1/118
Figure 2 Artemisinin responses of Plasmodium chabaudi AS-3CQ, AS-30CQ and AS-ART. Mean% parasitaemia ± standard error of groups of
three mice. A, untreated controls; B, 1 × 10exp6 parasites on day 0 and treated with 200mg ART/kg-1 day-1 days 1–3; C, 1 × 10exp7 parasites on
day 0 and treated with 200mg ART/ kg-1 day-1 days 1–5. AS-sens, blue; AS-30CQ, red; AS-ART, green.
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Table 1 Confirmed and high confidence mutations in the ART-resistant Plasmodium chabaudi clone AS-ART (relative to progenitor clone, AS-sens)
Chromosome Type Analysis Nucleotide
start
Nucleotide
end
reference
base
variant
base
SSAHA
quality
Confirmation of
mutation by
dideoxy
sequencing
P. chabaudi gene ID Amino acid
change
Nearest gene ID
(P. chabaudi)
P. falciparum
orthologue
SNPs
2 SNP SSAHA/MAQ 216,954 C A 99 confirmed* PCHAS_020720 V2728F PF3D7_0104300
3 SNP SSAHA/MAQ 70,553 G T 99 confirmed* PCHAS_030200 T707N None
3 SNP SSAHA/MAQ 474,123 C A 99 confirmed* PCHAS_031370 T719N PF3D7_0214800
7 SNP SSAHA/MAQ 994,546 G A 99 confirmed* PCHAS_072830 S106N PF3D7_0417200
10 SNP SSAHA/MAQ 634,932 T C 99 confirmed* PCHAS_101550 Y162H PF3D7_1430000
11 SNP SSAHA/MAQ 996,332 G T 99 confirmed* PCHAS_112780 A173E PF3D7_0629500
14 SNP SSAHA/MAQ 936,945 T G 92 confirmed* 5'-PCHAS_142600 PF3D7_0813400
14 SNP SSAHA/MAQ 1,270,184 T C 99 confirmed* PCHAS_143590 I568T PF3D7_1218300
approximate
size
comparative
coverage
Indels
4 indel SSAHA/MAQ 793,940 793,988 49 0.16 tbc** PCHAS_042080-5 None
5 deletion SSAHA/MAQ 683,724 684,989 1,266 0.21 tbc** PCHAS_051920 None
7 deletion SSAHA/MAQ 876,907 876,921 15 0.18 34bp deletion* PCHAS_072420-3' PF3D7_0815700
bin indel SSAHA/MAQ 261,129 284,496 23,368 0.02 tbc** PCHAS_000700-760 None
All point mutations and 34 bp deletion (*) were confirmed by di-deoxy sequencing. A small deletion on chromosome 4 and large deletions on chromosome 5 and ‘bin’ (**), have strong supporting evidence (extended
area of low and zero coverage, SNP-proxies for deletions). Base quality scores (which only apply to SNPs) are derived from the SSAHA2 algorithm (with 99 being the best score). For indels, the approximate size of the
affected area (as measured by SSAHA2) and a comparative coverage are given. Amino acid substitutions (non-synonymous mutations) are in bold characters. One point mutation in AP2-μ chain specific to AS-ART
(relative to preceding clone, AS-30CQ) is in bold and underline characteres. Tbc: to be confirmed.
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and AS-ART to 100 mg ART kg-1 d-1 (3 day) is called
ART-R phenotype 1.
Genome re-sequencing of AS-ART
AS-ART was sequenced using the Illumina platform using
36 base single-end reads. In total, 45,879,892 short single-
end reads were produced for clone AS-ART, of which 89%
were mapped onto the 2009 version of the reference
genome (Welcome Trust Sanger Institute P. chabaudi AS
parasite, AS-WTSI, genome size 18,832,196 bp [36]: by
the mapping software, SSAHA2. The mean genome-wide
read coverage was 84 reads per nucleotide (see Additional
file 2). Approximately 87% of the total reads (39,979,351)
were mapped in unique positions. Some 98% of the nucle-
otides in the genome were covered by at least 10 reads
and 93% by at least 40 reads; 1.67% was covered by less
than three reads (the minimum required for SNP and
small indel detection). Similar data were obtained using an
alternative mapping software, MAQ. Clones AS-sens
and AS-30CQ had been re-sequenced previously and
reads aligned similarly [25,26,28].
SNP detection
Preliminary SNP calling and filtering (see Methods) identi-
fied eight point mutations in AS-ART (Table 1), relative
to the resequenced clone AS-sens [25-28]. There were
11 additional low- quality SNP calls considered to be false
positives (see Additional file 3).
Eight point mutations identified by both Samtools
and MAQ had higher quality scores (≥92, maximum 99)
(Methods) than the other 11 (quality scores <34, see
Additional file 3) calls, and were subsequently verified
by di-deoxy sequencing in AS-ART (Table 1). Seven of
these eight were previously reported from the AS-ART
progenitor, AS-30CQ [25,26]. They include five point
mutations, previously linked to drug resistance phenotypes.
These are: a) S106N dhfr (encoding dihydrofolate reduc-
tase) (PCHAS_072830), (quality score: 99), which confers
pyrimethamine resistance [28]; b) A173E (quality score: 99)
in an amino acid transporter (aat1, PCHAS_112780), con-
ferring chloroquine resistance [26]; c) T719N (quality score:
99) in a hypothetical protein (PCHAS_031370) confer-
ring intermediate chloroquine resistance [26]; and, d) a
V2728F (quality score: 99) substitution in the ubp1 gene
(PCHAS_020720), conferring artemisinin resistance
phenotype 1 [25], high-level chloroquine resistance [26]
and mefloquine resistance [27]. A fifth point mutation
namely T707N (quality score 99) in a member of the
P. chabaudi-specific interspersed repeat (cir) gene family
(PCHAS_030200) may also contribute to the intermediate
CQ-R phenotype of AS-30CQ [26]. In all cases, the
position of their appearance in the P. chabaudi AS lineage
coincides with the appearance of the corresponding drug-
resistance phenotype.
Two point mutations have not been linked to any par-
ticular phenotype. These are: Y162H (quality score 99) in a
gene annotated as a hypothetical protein (PCHAS_101550)
appearing first in AS-30CQ, and an intergenic mutation
(quality score: 92) at base position 936,945 on chromo-
some 14, located between genes PCHAS_142590 and
PCHAS_142600 (both hypothetical proteins with no sig-
nificant Pfam matches), first appearing in AS-PYR1, the
first drug-resistance clone of the lineage.
One point mutation only in clone AS-ART relative to
AS-30CQ was confirmed. This mutation was I568T (qual-
ity score 99) in a gene (PCHAS_143590) predicted to
encode the mu (μ) chain of the AP2 adaptor protein
complex, which, in other organisms, is involved with
clathrin-mediated endocytosis [45]. This gene was de-
noted ap2-μ.
In contrast to the eight confirmed mutations above,
the other 11 low-quality calls (see Additional file 3, high-
lighted in orange) were predicted only by Samtools; nine of
these have extremely low Samtools quality scores (2 to 13)
and were variously mapped to the extreme ends of chrs 01,
03, 07 (two), 10 and 12, where P. chabaudi-specific genes
are located (often in multigene families), or to contigs yet
to be mapped to the final genome assembly (three in
‘bin’). Here, read alignment may be less reliable, as
reflected in their low mapping quality. A similar low
quality SNP call in AS-30CQ was previously identified
as a false positive by di-deoxy-sequencing [28]. Accord-
ingly, these nine low confidence SNPs are strongly pre-
dicted to be false positives. In any case, their genomic
locations suggest that they would be unlikely to play a
role in a conserved artemisinin resistance phenotype
because four of these candidates were intergenic (chr01,
03, 07, 10) and the other five (chr07, 12 and bin (three))
were in genes without orthologues in P. falciparum, in con-
trast to the eight confirmed point mutations.
The two remaining low confidence point mutations
mapped to chr05 or contig11844 and had higher quality
scores (33 and 31, respectively). However, they were lo-
cated close to, or within extended regions of low coverage
proposed to be deletions (one of which, on chr05, was pre-
viously noted) [26], see below. False positive SNPs such as
these were previously termed ‘proxies for deletions’ and
their artefactual appearance explained [25].
It is concluded that the I568T mutation in the gene
PCHAS_143590 encoding the mu (μ) chain of the AP2
adaptor protein complex is likely to be the only point
mutation in AS-ART relative to its immediate precursor
AS-30CQ.
Small indels, larger deletions and CNV detection
Forty-one potential insertions or deletions (indels) (14 larger
(>3bp) indels, 27 small (≤3 bp) indels) and seven potential
copy number variants (CNVs) were called (see Additional
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files 4, Additional file 5 and Additional file 6) in AS-ART
relative to AS-sens. The specific detection and identifica-
tion of large insertions was not feasible because the
single-end sequencing data used in these studies were
not able to support the use of more sophisticated detec-
tion algorithms that depend upon the availability of
paired-end data.
The 27 small indels were considered to be low confi-
dence predictions, ie, false positives. Dideoxy-sequencing
confirmed that the five tested were all false positives (see
Additional file 4), as in previous studies of AS-15MF and
AS-30CQ [25,28]. It is suggested that the majority of these
predicted low confidence mutations are therefore false
positives. In any case, only six of the other 22 small indels
were intragenic.
For larger indels, analysis based on read depth reveals
large deletions (say >20 bp) with greater reliability than
for intermediate deletions (say 3<bp<20) and all larger
insertions. Four (see Additional file 5, highlighted in yel-
low) of the 14 intermediate and large indels candidates
were classified as high confidence mutations (Table 1,
Methods), principally because they were predicted using
both MAQ and SSAHA2 but also because they generate
consistently low read coverage over an extended region.
Also, three (chr04, 05, 07) were previously identified in the
progenitor clone AS-30CQ or in a related clone AS-15MF
[25,26]. One of these was previously confirmed by dideoxy-
sequencing as an intergenic 34 bp deletion on chr07.
Another was a potential large deletion (>1 kb) on chromo-
some 5 located within a gene coding for a non-syntenic
(ie, its chromosomal location is not conserved across
malaria species relative to surrounding genes) S-antigen
(PCHAS_051910-20). The third was a deletion in non-
coding sequence at the right hand end of chromosome
4, in a region previously defined to be the site of dele-
tion and translocated copy of a large duplicated chr12
fragment containing mdr1 in the related clone AS-15MF
[27]. The remaining high confidence large deletion corre-
sponds to a potential ~23 kb deletion on an unassigned
contig (‘bin’ contig11844), not predicted in the progenitor
clone AS-30CQ, spanning several non-syntenic genes
(PCHAS_000700 to PCHAS_000760). The regions cor-
responding to deletions on chr05 and in contig 11844
also contain an example of a SNP ‘proxy for deletion’
(see section above). Verification of the three deletions
(in chr04, chr05 and contig 11844) by di-deoxy sequen-
cing was not possible due either to their size or position
or both. For the other 10 larger deletion candidates,
six are intergenic and four are predicted to interrupt
P. chabaudi-specific genes, three mapping to the ex-
treme ends of chr13 (two) and chr14, and one to an un-
assigned contig (see Additional file 5).
It is worth noting that the frequency of indels in the
chicken and human genomes (e.g. [46,47]) is less than
the SNP frequency; confirmed in next generation short-
sequencing analysis [48]. If applicable to Plasmodium
spp, the number of indels will be less than the number
of point mutations. Since the number of point mutations
in AS-ART (relative to AS-sens) is likely to be eight, the
four high-confidence deletions detailed above may repre-
sent the full complement of indels. Only one (in contig
11844) appears in AS-ART, relative to AS-30CQ.
For the seven potential CNVs, identified by higher read
comparative coverage (range 1.5 – 3.1), they extend over
very small regions (205–282 bp) and lie outwith coding
regions of genes (see Additional file 6). In other clones
of the P. chabaudi AS lineage, previously validated large-
fragment CNVs (involving mdr1) were identified using a
similar comparative read-coverage analysis ([27] and data
not shown). In the present case, the seven potential CNVs
are unlikely to represent gene duplication/amplification
events, simply reflecting natural variation of read coverage.
It is likely that there is only one high-confidence deletion
(contig 11844) arising in AS-ART relative to AS-30CQ.
The likelihood of other indels or CNVs arising in AS-ART
is considered to be low and, in any case, unlikely to confer
artemisinin resistance phenotype 2.
Conservation and structure of AP2 μ-chain
An alignment of the predicted amino acid sequences of
AP2-μ of P. chabaudi (PCHAS_143590, 597 aa) and its
P. falciparum orthologue, PF3D7_1218300 (Figure 3A)
and other Plasmodium spp (data not shown) confirm that
this gene is highly conserved in Plasmodium spp. Specific-
ally, the I568T mutation appears close to the C-terminus
in a particularly highly conserved region. BLAST searches
identify AP2 adaptor μ-chains from other species such as
R. norvegicus (435 aa) (Figure 3B) showing high sequence
conservation in both the N-terminal domain (aa 1–154,
numbering P. chabaudi unless otherwise stated) and the C-
terminal domain (aa 244–597) which forms two subdomains
each composed of a β-sheet. These large regions of β-sheets
bind to, and hence select cargo protein during coated pit
formation and vesicle formation during endocytosis [45,49].
In addition to the conservation of its amino acid sequence,
other sequence and structural features of PCHAS_143590
support its designation as the μ-chain of the AP2 adaptor
complex and a role in recognition of cargo protein and
endocytosis. Residues 155 to 243 comprise Plasmodium
specific sequence and extend the linker (rat136 – 158) be-
tween the AP2-μ N-terminal and C-terminal domains. At
its C-terminal end, this linker contains T245, homologous
to rat T156 that requires phosphorylation for endocytosis
in vitro and in vivo [50]. Also, the P. chabaudi protein
contains 17 lysine residues (aa 410 – 537) in a region
where positively charged patches in rat μ chain interact
with phosphatidylinositol bisphosphate (PIP2) [51]. Both
phosphorylation and PIP2 or PIP3 binding stabilize a large
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Figure 3 (See legend on next page.)
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conformational change that allows cargo signal motifs to
access the μ-chain signal recognition site at the membrane
surface [52].
BLAST alignments (Figure 3A, 3B) support the designa-
tion of P. falciparum I592 and R. norvegicus V401 as the
corresponding residues to P. chabaudi I568, suggesting
that these residues will have similar positions within the
protein structure, and therefore, a corresponding func-
tional significance.
X-ray structures for both the μ-chain alone or the
adaptor complex cocrystallised with peptides containing
YXXΦ (where Φ represents a hydrophobic residue such
as F, I, V, L or M) recognition motifs on the target (cargo)
ligands [53] include a rat μ-chain structure (pdb 2PR9),
showing that the V401 residue of the rat μ-chain is adjacent
to the L9 Φ residue (L, lysine) of the bound DEEYGYECL
peptide and, along with rat L173, L175, L404 and V422,
forms a hydrophobic pocket into which the Φ residue
binds (Figure 4A). The high sequence conservation be-
tween PCHAS_143590 and the rat AP2 μ-chain (Figure 4B,
Figure 3B) suggests that I568 will play a similar role in
the P. chabaudi AP2 adaptor to that of V401 in the rat
homologue. Homology models of the P. chabaudi struc-
ture were predicted by threading the P. chabaudi amino
acid sequence into the rat crystal structure, using I-TASSER.
The resulting structures indeed show that I568 (P. chabaudi,
Figure 4B) and I592 (P. falciparum, Figure 4C) are predicted
to lie in a corresponding position, relative to the Φ residue
in the bound peptide. The likely effect of the I568T muta-
tion was investigated in the P. chabaudi homology model.
The most likely conformation of 568T was predicted by
minimising the contact of the side chain oxygen atom in
568T to nearby hydrophobic residues. This results in
the oxygen pointing towards the solvent, hence forming
part of the Φ-binding pocket (Figure 4D). The effect of
the 568T hydroxyl group is therefore to add some
hydrophilic character to the hydrophobic pocket into
which the Φ residue fits. Similar results were obtained
for the P. falciparum μ2 homology model (data not shown).
The I568T mutation is predicted to moderate but not abro-
gate the binding of the μ subunit to the YXXΦ recognition
motif present in the cargo protein. In any case, at least in
yeast, an AP-2 μ-chain knock-out is not lethal [54] and
clathrin may function independently of the adaptor [55].
Polymorphisms in Plasmodium falciparum ap2-μ gene
Because the only confirmed point mutation arising in
P. chabaudi AS-ARTalong with ART resistance phenotype
2 lies in the AP2-μ gene, the polymorphisms in the
P. falciparum orthologue (PF3D7_1218300) were investi-
gated. The DNA sequence analysis of PF3D7_1218300 in
24 samples (see Additional file 2) from Brazil, São Tomé
and Rwanda revealed a total of 12 independent poly-
morphic sites, consisting of nine SNPs and three indels.
Seven SNPs and all the insertions were novel genetic
variants (relative to existing information in PlasmoDB,
Table 2) and unrelated to each other. A polymorphism
similar to P. chabaudi I568T was not detected in any of
the isolates inspected.
Five of the nine SNPs were non-synonymous (aa 146,
160, 199, 233 and 437) while four were synonymous
(Table 2). The non-synonymous mutations R146K, S160N
and F437L occur within regions which appear to be well
conserved in Plasmodium spp of the N-terminal domain
of AP2-μ (Figure 3A), although residues in these regions
are not well-conserved relative to the rat homologue
(Figure 3A, B). The non-synonymous SNPs, K199T and
N233K are situated in unconserved regions. The three
indels were three-nucleotide insertions of an AAT codon
(asparagine) found adjacent to codon 233, 324 or 329 in
asparagine-rich sequence (Table 2) not conserved in the
P. chabaudi orthologue. Amino acids 324 and 329 are
located on a P. falciparum-specific region relative to
both P. chabaudi and the rat homologue (Figure 3A, B).
Discussion
Increased artemisinin resistance phenotype
An ART resistance phenotype (phenotype 1) in P. chabaudi
was previously described and the underlying genetic mech-
anism (mutations in ubp1) identified [25]. That pheno-
type had been experimentally evolved in AS-30CQ under
chloroquine selection and without any exposure to ART.
Subsequently AS-ART was evolved from AS-30CQ by ART
selection [29]. Here, an increased artemisinin resistance
(phenotype 2) in AS-ART relative to AS-30CQ is charac-
terized. The increased resistance is apparent at 200 mg
ART kg-1 d-1 (inoculation of 106 parasites, three-day drug
treatment). Interestingly a five-day treatment using a higher
inoculum (107 parasites) also differentiated AS-ART from
AS-30CQ. These data are consistent with the hypothesis
that quiescence or dormancy responses may underlie sur-
vival of artemisinin treatment [56,57].
Genetic basis of increased artemisinin resistance
Illumina whole-genome sequencing reveals a single point
mutation arising between AS-30CQ and AS-ART. This
(See figure on previous page.)
Figure 3 Conservation of AP2 μ-chain amino acid sequence. Conservation between P. chabaudi (PCHAS_143590) sequence and A) P. falciparum
(PF3D7_1218300) or (B) rat (P84092 UniProtKB/Swiss-Prot) sequences. The P. chabaudi mutated residue I568 and the corresponding P. falciparum
residue I592 (A) and Rat V401 (B) are highlighted (purple). Note Plasmodium spp.-specific sequence (~90 residues, relative to rat) lying between
positions 154–244 (P. chabaudi).
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Figure 4 I568T mutation in AP2 μ-chain interacts with YXXΦ motif on cargo protein. A. Rat (P84092) V401 is homologous to P. chabaudi
AP2 μ-chain I568, and contributes to the hydrophobic pocket that binds L9 residue of bound peptide (DEEYGYECL) in structure 2PR9. B. Homology
model for P. chabaudi wild-type homologue shows similar structure with I568 corresponding to rat V401. C. Homology model for P. falciparum
orthologue shows similar structure, with I592 corresponding to rat V401 and P. chabaudi I568. D. Homology model for P. chabaudi mutant - 568T is
predicted to reduce the hydrophobic character of the binding pocket in which peptide L9 binds. Note increased polar character associated with
threonine hydroxyl group in D relative to B.
Table 2 Genetic polymorphisms identified in the pfap2-μ gene (PF3D7_1218300)
Nucleotide Reference sequence (3D7) variant Codon, variant Amino acid substitution Location
300 ATA ATC I100syn Rwanda
381 GTG GTT*/GTC V127syn Brazil
437 AGA AAA R146K Rwanda
479 AGT AAT S160N Rwanda, STP
486 ATT ATC I162syn Rwanda
489 GAA GAG* E163syn Rwanda, STP
596 AAA ACA K199T Rwanda
699 AAT AAG N233K Rwanda
1311 TTC TTA F437L Rwanda
Insertions
Codon insertion Amino acid insertion
699 AAT AATAAT 233 + N STP
972 AAT AATAAT 324 + N Rwanda, STP
987 AAT AATAAT 329 + N STP
Polymorphic bases are underlined. * - SNP previously identified and recorded in PlasmoDB. Non-synonymous SNPs are shown with amino acid substitutions
(bold). STP, Sao Tome and Principe.
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mutation encodes an I568T substitution in the μ subunit
of the AP2 adaptor complex (PCHAS_143590). The num-
ber of false negatives due to insufficient coverage is esti-
mated to be less than one/genome, as previously discussed
[25,26] and given the minimum threshold for point
mutation detection (three reads), the proportion of the
genome covered by less than three reads (1.67%, see
Additional file 4) and the accurate identification of simulated
mutations (random alterations in reference sequence) [25].
The frequency of a false negative arising from incorrect read
alignment is minimized because the re-sequenced and refer-
ence genomes are largely identical, and because optimal
hashing-table algorithms were used. Importantly the likely
appearance of only one point mutation is consistent with
previous genome re-sequencing studies [26] that reveal a
consistent set of a small number of point mutations, most
of which confer drug-resistance phenotypes in other drug-
resistant clones of the P. chabaudi AS lineage (Table 1)
[25-28]. For example, four or five out of seven single nucleo-
tide substitutions between AS-sens and AS-30CQ confer
resistance to pyrimethamine, chloroquine and artemisi-
nin phenotype 1 [25,26]. This is consistent with similar
studies using other parasites; for example, only four non-
synonymous mutations arose in each of two miltefosine-
selected Leishmania major genomes [58].
Although the possibility that increased ART-R is con-
ferred by unidentified point mutations in the small fraction
of the unassembled genome cannot be excluded, regions
of low read coverage, the indel identified in AS-ART, or
further unidentified indels, suggest that the mutation
I568T in AP2-μ on chr14 is the principal determinant of
higher-level artemisinin resistance (ART-R phenotype 2)
in AS-ART which also bears the ubp1 mutation [25] but
no mdr1 amplification [27]. This hypothesis should be
validated by transfection experiments.
Other results are consistent with this hypothesis. A pre-
vious study suggested that a locus on chr14 contributes
to artemisinin responses in genetic selection experiments
using AS-ART [23]. Also, two recent independent reports
show evidence of the involvement of adaptor proteins in
drug resistance phenotypes in other human parasites. A
genome-wide RNAi target sequencing approach revealed
Trypanosoma brucei parasites with a knockdown of one
of each of the four AP1 adaptor subunit genes (as well
as lysosomal proteases, vacuolar protein sorting factors,
etc.) of the endosomal system in suramin-treated popu-
lations [59]. In a similar experimental paradigm to that
described here, an in vitro miltefosine-resistant L. major
line bore a D762 mutation in the α-subunit of an adaptor
protein and a different mutation in the Leishmania infantum
orthologue [58]. The probability that mutations in adaptor
subunits confer resistance to three structurally and function-
ally unrelated drugs (suramin, miltefosine and artemisinin)
in three different parasites (Trypanosoma, Leishmania and
Plasmodium) suggests that a conserved aspect of drug treat-
ment and response is targeted by these mutations.
Clathrin-mediated endocytosis - insights regarding ART
action and resistance
The AP2 adaptor complex is a heterotetramer (α, β, μ, σ)
that selects and recruits other factors, including mem-
brane protein (cargo) and intracellular clathrin, mediating
clathrin-mediated endocytosis (CME) [45]. CME is involved
in the internalization of extracellular molecules and ligands
(e g, low density lipoprotein, transferrin, growth factors,
antibodies and bacterial toxins), the remodelling of the
plasma membrane (removal of variable antigen), and mem-
brane protein trafficking and vesicular sorting through the
endosomal system and lysosomes [49]. In P. falciparum,
these cellular processes are being studied particularly
regarding digestive vacuole genesis, haemoglobin uptake
and digestion [60], the role of (poly)phosphorylated phos-
phatidyl inositol [61], the action of aminoquinolines and
artemisinins [6,7,62-64] and the trafficking of a critical
determinant of chloroquine resistance (the membrane
protein, crt) [65]. The participation of clathrin (as coated
vesicles) in endocytosis and its relationship to the forma-
tion of cystosomes has not been fully clarified and, in any
case, the mechanism would require the production of
vesicles with double membranes (parasitophorous vacuole
and parasite membranes). Nevertheless, it is possible that
some elements of CME have been recruited to the haemo-
globin uptake mechanism. The existence of Plasmodium-
specific additional sequence between the N- and C-terminal
domains of the AP2-μ chain may reflect non-canonical
functional attributes of the AP2 adaptor complex.
The I568T mutation in the AP2 μ-chain locates to a
residue forming a hydrophobic pocket into which the Φ
residue of the YXXΦ recognition motif on the cargo
proteins binds. This suggests that modulation of cargo
trafficking may be the key event in this resistance path-
way. The I568T mutation in AP2-μ may reduce its binding
to membrane cargo and mediates artemisinin resistance
phenotype 2 by reducing endocytosis or the recycling or
trafficking of one or more membrane proteins. Previous
work has shown that fluorescent artemisinin derivatives
concentrate in neutral lipid bodies close to the digestive
vacuole [5], suggesting that drug may be taken up by
endocytosis. Artemisinin interacts with the endocytic and
endosomal pathway. For example, it inhibits endocytosis
[62] and haemoglobin uptake [7], resulting in the disrup-
tion of the DV membrane [6] and some derivatives may
increase the accumulation of endocytic vesicles [6]. Also,
artemisinin activity is dependent on haemoglobin diges-
tion [7]. A reduction in haemoglobin uptake or digestion
may therefore constitute a strategy for surviving expo-
sures to short-lived artemisinins. The I568T mutation
might therefore reduce the rate of haemoglobin uptake
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and hence the activation or action of artemisinin. Indeed,
the reduced growth of AS-ART in relation to its sensitive
progenitor AS-30CQ in absence of treatment (Figure 2A),
indirectly supports this notion. The involvement of adaptor
proteins in resistance to suramin, miltefosine and artemisi-
nin in Trypanosoma, Leishmania [66,67] and Plasmodium
however, may suggest a rather general resistance mechan-
ism involving, for example, the reduction of drug uptake
through endocytosis.
A V2728F mutation in ubp1 was previously identified as
the critical determinant of artemisinin resistance pheno-
type 1 in AS-30CQ [25], predicting that this mutation
would decrease de-ubiquitination. The ubiquitination of
membrane receptors and proteins may induce clathrin-
independent (caveolae) endocytosis [68]. Therefore, the
ubp1 and AP2-μ mutations may both modulate endocyto-
sis, possibly changing the balance of endocytosis toward a
clathrin-independent pathway. Interestingly, chloroquine
is also known to interact with endocytosis, vesicular trans-
port, haemoglobin digestion and actin and DV dynamics
[62-64,69] and the V2728F ubp1 mutation has been shown
to confer high-level CQ-resistance [26]. This artemisinin-
and chloroquine-cross resistance is therefore consistent
with the suggestion that endocytic pathways are involved in
the mode of action of both of these drugs and the resist-
ance mechanisms in P. chabaudi.
The present study therefore suggests that experimental
studies on the molecular interactions between ubiquitination
pathways, endocytosis and artemisinin uptake and sensi-
tivity may provide important insights regarding artemisi-
nin action and resistance mechanisms.
Field studies of Plasmodium falciparum
12 genetic polymorphisms (nine SNPs and three inser-
tions) were identified in the P. falciparum orthologue
(PF3D7_1218300) in field samples from Rwanda, São Tomé
and Brazil. Further studies will therefore be required to
evaluate the association between PF3D7_1218300 poly-
morphisms and artemisinin responses. Association studies
in locations in Southeast Asia where ART-R has been
reported would be of particular interest. A recent linkage
analysis of a P. falciparum genetic cross (HB3 × Dd2) re-
vealed three loci linked to in vitro artemisinin responses;
on chr05, chr12 and chr13 [24]. Marker C12M63 was the
most highly linked marker on chr12. However, this marker
maps over 1 Mbase downstream from PF3D7_1218300
suggesting that a different gene was involved in that study.
A genome-wide analysis of genetic diversity in P. falciparum
parasites from Asia, with different artemisinin responses
mapped a possible genetic determinant to a region of chr13
[21]. However, no SNPs were identified in these genes that
could be associated with the in vivo parasite’s responses to
ART. Recently however, the genotyping of P. falciparum iso-
lates from Asia established associations between four SNPs
(on chromosomes 10, 13 and 14) and both recent positive
selection and parasite clearance phenotypes after artemisinin
treatment [70]. However, the genes and regions where these
SNPs lie are not linked to the P. falciparum orthologue of
the AP2 μ-chain on chromosome 12, suggesting a different
gene to that identified here is involved
Conclusions
An increased artemisinin resistance phenotype in a lineage
of P. chabaudi drug-resistant parasites was identified.
Genome-wide re-sequencing identifies a single point mu-
tation in a critical part of the AP2 adaptor μ-chain. This
mutation is predicted to increase artemisinin resistance by
modulating clathrin-mediated endocytosis. Analysis of
the orthologous gene in P. falciparum field isolates dem-
onstrates existing genetic variation in the human malaria
parasite.
Lastly, the possibility was considered that mutations in a
different gene(s) may play a role in responses to artemisi-
nin derivatives in P. falciparum. However, further than
assigning particular mutations to ART resistance pheno-
types, it is suggested that a potentially novel biological
pathway through which artemisinin resistance may occur
may be involved.
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